Safety of recombinant factor VIIa in patients under extracorporeal membrane oxygenation

Amédéo Anselmi(Inserm), Erwan Flécher(Inserm), Bernard Lelong(Centre Hospitalier Universitaire de Rennes), Vito Giovanni Ruggieri, Yannick Mallédant(Inserm), Jean‐Philippe Verhoye(Laboratoire Traitement du Signal et de l'Image), Pierre Guéret(Hôpital Pontchaillou), Solène Granry(Hôpital Pontchaillou), Marie Aymami(Hôpital Pontchaillou), Yves Le Tulzo, P Guinet(Naropa University)

European Journal of Cardio-Thoracic Surgery

April 23, 2015

10.1093/ejcts/ezv140

Cited by 32

Related Papers

Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass

|JAMA|2017|193

Predictors and Clinical Impact of Late Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices

|JACC. Clinical electrophysiology|2018|99

Venous territories of the brain.

|PubMed|1994|93

Pressure-Support Ventilation vs T-Piece During Spontaneous Breathing Trials Before Extubation Among Patients at High Risk of Extubation Failure

|CHEST Journal|2020|90

Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study

|Intensive Care Medicine|2022|82